Leading Innovation in the Life Sciences
New York Bio Connect aims to simplify and amplify the state and city’s life sciences ecosystem, organizing opportunities from Manhattan to Buffalo to position students, entrepreneurs, investors, policy makers, and established industry leaders for success.
Funding
Investing in innovation
Careers
Your future starts here
The Latest
HHS and FDA propose clinical trial reforms to expedite drug development
The US Food and Drug Administration (FDA) is seeking comments on a pilot program where qualified external institutions will collaborate with sponsors to develop and review protocols for first-in-human (FIH) clinical trials intended for investigational new drug (IND) submissions to FDA. The two key initiatives were announced as part of a broader program by the…
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
The FDA granted Breakthrough Device Designation to NSE-FAST® (Neuron Specific Enolase – Functional Activity Stroke Test), a rapid blood test from TETmedical, Inc. positioning them as the first rapid test to aid in diagnosing acute ischemic stroke.Stroke is the #1 condition tied to serious misdiagnosis harm in U.S. emergency departments with roughly 17% of strokes…
New report details how U.S. can maintain biotech competitiveness
A new report from the Reagan-Udall Foundation for the FDA, funded by BIO, warns that the United States is on the verge of losing its historic lead in drug development—its share of the global pipeline has slipped from 47% in 2013 to 36% in 2025 as China closes the gap. To stay competitive, the report…
Why a global health organization just placed a $10M bet on Buffalo
A University at Buffalo startup developing next-generation vaccine technology has secured up to $9.7 million from the Coalition for Epidemic Preparedness Innovations, recognition that its platform could play an important role in the rapid deployment of vaccines against emerging infectious diseases. The non-dilutive funding marks a significant milestone for POP Biotechnologies, positioning the Buffalo company…
FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons
FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced the close of an oversubscribed $20 million Series A financing round. The round was anchored by Jefferson Life Sciences (JLS) and joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development’s NY Ventures,…
LIFE SCIENCES IN NEW YORK
Where science and opportunity come together
New York’s life science sector has attracted unprecedented investment, expanded research clusters across the state, and nurtured the growth of early-stage companies.
#2
NATIONAL R&D SPEND
100,000+
LIFE SCIENCES JOBS
25%
CLINICAL TRIALS IN THE U.S.